CN106459022B - 抗真菌化合物的制备方法 - Google Patents

抗真菌化合物的制备方法 Download PDF

Info

Publication number
CN106459022B
CN106459022B CN201580014312.0A CN201580014312A CN106459022B CN 106459022 B CN106459022 B CN 106459022B CN 201580014312 A CN201580014312 A CN 201580014312A CN 106459022 B CN106459022 B CN 106459022B
Authority
CN
China
Prior art keywords
mixture
alkyl
aryl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580014312.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459022A (zh
Inventor
威廉·J·胡克斯特拉
克里斯多夫·M·耶茨
马克·本克
阿萨夫·阿利马达诺夫
斯科特·A·大卫
道格拉斯·弗兰克林·弗莱依
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina - Yameite Pharmaceutical Co
US Department of Health and Human Services
Original Assignee
North Carolina - Yameite Pharmaceutical Co
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina - Yameite Pharmaceutical Co, US Department of Health and Human Services filed Critical North Carolina - Yameite Pharmaceutical Co
Publication of CN106459022A publication Critical patent/CN106459022A/zh
Application granted granted Critical
Publication of CN106459022B publication Critical patent/CN106459022B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Artificial Filaments (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
CN201580014312.0A 2014-03-19 2015-03-19 抗真菌化合物的制备方法 Expired - Fee Related CN106459022B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955532P 2014-03-19 2014-03-19
US61/955,532 2014-03-19
PCT/US2015/021464 WO2015143154A1 (en) 2014-03-19 2015-03-19 Antifungal compound process

Publications (2)

Publication Number Publication Date
CN106459022A CN106459022A (zh) 2017-02-22
CN106459022B true CN106459022B (zh) 2019-08-02

Family

ID=54145313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580014312.0A Expired - Fee Related CN106459022B (zh) 2014-03-19 2015-03-19 抗真菌化合物的制备方法

Country Status (12)

Country Link
US (2) US10077250B2 (enExample)
EP (1) EP3119771B1 (enExample)
JP (1) JP6606508B2 (enExample)
KR (1) KR20160138013A (enExample)
CN (1) CN106459022B (enExample)
AU (1) AU2015231208B2 (enExample)
BR (1) BR112016021282A8 (enExample)
CA (1) CA2942930A1 (enExample)
EA (1) EA201691648A1 (enExample)
ES (1) ES2800905T3 (enExample)
MX (1) MX369357B (enExample)
WO (1) WO2015143154A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143162A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) * 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
CA2942972A1 (en) 2014-03-19 2015-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antifungal compound process
BR112016020937B1 (pt) 2014-03-19 2022-09-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Processo de preparação de compostos antifúngicos
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP2017514790A (ja) 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
EP3119748A4 (en) 2014-03-19 2017-08-30 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX369357B (es) * 2014-03-19 2019-11-06 Mycovia Pharmaceuticals Inc Procedimiento de compuesto antifungico.
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
JP6887993B2 (ja) 2015-09-18 2021-06-16 エヌキューピー １５９８，リミテッド 抗真菌化合物調製方法
EP3710432A1 (en) 2017-11-13 2020-09-23 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097374A (zh) * 2010-04-24 2013-05-08 威尔金制药有限公司 金属酶抑制剂化合物
WO2013109998A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013110002A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
US20120088664A1 (en) 2009-06-18 2012-04-12 Basf Se Antifungal 1,2,4-triazolyl derivatives having a 5-sulfur subtituent
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
JP6159318B2 (ja) 2011-06-19 2017-07-05 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害化合物
AU2012273007A1 (en) 2011-06-23 2014-01-30 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
AU2012352555B2 (en) * 2011-12-11 2017-08-03 Nqp 1598, Ltd. Metalloenzyme inhibitor compounds
WO2014043376A1 (en) 2012-09-12 2014-03-20 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
JP2016508487A (ja) 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
EP3004067A4 (en) * 2013-05-28 2016-10-12 Viamet Pharmaceuticals Inc FUNGICIDE COMPOSITIONS
KR20160018811A (ko) 2013-06-12 2016-02-17 비아멧 파마슈티컬즈, 인코포레이티드 금속 효소 억제 화합물
CA2942972A1 (en) 2014-03-19 2015-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antifungal compound process
BR112016020937B1 (pt) 2014-03-19 2022-09-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Processo de preparação de compostos antifúngicos
JP2017514790A (ja) 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
WO2015143162A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
CA2942927A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119748A4 (en) 2014-03-19 2017-08-30 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX369357B (es) 2014-03-19 2019-11-06 Mycovia Pharmaceuticals Inc Procedimiento de compuesto antifungico.
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
BR112016021257B1 (pt) 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos
DK3271347T3 (da) 2015-03-19 2022-07-18 Mycovia Pharmaceuticals Inc Antifungale forbindelser og fremstillingsfremgangsmåder
EP3297998B1 (en) 2015-05-18 2019-12-11 Viamet Pharmaceuticals (NC), Inc. Antifungal compounds
JP6887993B2 (ja) 2015-09-18 2021-06-16 エヌキューピー １５９８，リミテッド 抗真菌化合物調製方法
EP3376865B1 (en) 2015-11-17 2021-04-14 Dow Agrosciences LLC 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h
AR106729A1 (es) 2015-11-17 2018-02-14 Viamet Pharmaceuticals Inc 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-oxoetil)piridin-3-il)oxi)benzonitrilo y proceso para su preparación
KR20180101342A (ko) 2015-11-17 2018-09-12 다우 아그로사이언시즈 엘엘씨 4-((6-(2-(2,4-디플루오로페닐)-1,1-디플루오로-2-히드록시-3-(1h-1,2,4-트리아졸-1-일)프로필)피리딘-3-일)옥시)벤조니트릴 및 제조방법
EP3377480A4 (en) 2015-11-17 2019-04-10 Dow AgroSciences LLC 4 - ((6- (2,4-DIFLUROPHENYL) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-YL) PROPYL) PYRIDINE-3-YL) OXY ) BENZONITRILE AND METHOD OF PREPARING THEREOF
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097374A (zh) * 2010-04-24 2013-05-08 威尔金制药有限公司 金属酶抑制剂化合物
WO2013109998A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013110002A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
MX369357B (es) 2019-11-06
EP3119771B1 (en) 2020-05-06
BR112016021282A8 (pt) 2021-07-20
KR20160138013A (ko) 2016-12-02
JP2017507993A (ja) 2017-03-23
US20170144990A1 (en) 2017-05-25
BR112016021282A2 (enExample) 2017-08-15
ES2800905T3 (es) 2021-01-05
EP3119771A4 (en) 2017-11-22
WO2015143154A1 (en) 2015-09-24
JP6606508B2 (ja) 2019-11-13
CA2942930A1 (en) 2015-09-24
AU2015231208B2 (en) 2019-04-04
EP3119771A1 (en) 2017-01-25
US10077250B2 (en) 2018-09-18
MX2016012053A (es) 2017-04-27
CN106459022A (zh) 2017-02-22
US20190177298A1 (en) 2019-06-13
AU2015231208A1 (en) 2016-10-06
EA201691648A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
CN106459022B (zh) 抗真菌化合物的制备方法
US10836740B2 (en) Antifungal compound process
CN109970629B (zh) 抗真菌化合物的制备方法
AU2015231234B2 (en) Antifungal compound process
JP6572234B2 (ja) 抗真菌化合物の調製方法
AU2015231220B2 (en) Antifungal compound process
AU2015231238B2 (en) Antifungal compound process
HK1234744B (zh) 抗真菌化合物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: North Carolina

Applicant after: VIAMET PHARMACEUTICALS, Inc.

Applicant after: U.S. Government Department of Health and Human Services

Address before: North Carolina

Applicant before: VIAMET PHARMACEUTICALS, Inc.

Applicant before: U.S. Government Department of Health and Human Services

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190802